IGC Pharma is developing an AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear.
The platform, called MINT-AD (Multimodal Interpretable Transformer for Alzheimer's Disease) will include data from neuroimaging, genomic profiles, cognitive test scores, lifestyle, behavioral, and digital biomarkers, and sociodemographic and environmental factors, the company explained.
IGC expects to launch a beta version of MINT-AD in 2026 for pilot evaluation in collaboration with academic and clinical partners, it said.
